2021 Pediatric Grand Rounds | Trials and Tribulations: Path Forward in Relapsed/Refractory Neuroblastoma Therapy
Neuroblastoma is one of the most common types of pediatric solid tumors and yet targeted immunotherapy of this disease is very limited. Pediatric oncologists need to stay abreast on advances in neuroblastoma management in order to apply the current state of the field to pediatric malignancies where appropriate. It is therefore, imperative that they hear from a leading expert in the field, to understand how the results of molecular evaluations alter management. Genomic advances have altered the landscape of neuroblastoma management. As more data is acquired, risk stratification and therapy continues to evolve.
City of Hope Pediatric Hematology/Oncology Physicians, Advance Practice Practitioners, City of Hope staff and research teams.
- Integrate advances in neuroblastoma management into current practices.
- Discuss applicability of these advances to management of other pediatric malignancies.
- Identify risk stratification by molecular evaluations in pediatric neuroblastoma.
Virtual Meeting- Zoom
Araz Marachelian, MD, MS Assistant Professor of Pediatrics, University of Southern California; Medical Director, NANT Operation’s Office; Children’s Hospital Los Angeles
Dr. Marachelian has indicated that is receives Grant/Research Support from Pfizer and United Therapeutics; Consultant for United Therapeutics and YmAbs Therapeutics.
Dr. Marachelian will be discussing the off-label or investigational use of isotretinoin, cyclophosphamide, topotecan, dinutuximab, dinutiximab-Beta, accutane, cisplatin, metaiodobenzylguanidine (MIBG), irinotecan-temozolomide, temsirolimus, vincristine, irinotecan, omburtamab, alisertib, crizotinib, lorlatinib, and vorinostat.
ACCREDITATION STATEMENT: City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CREDIT DESIGNATION: City of Hope designates this live webinar for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The following credit type(s) are being offered for this course:
• AMA PRA Category 1™ 1.0
The following may apply AMA PRA Category 1 Credit™ for license renewal:
Registered Nurses: Nurses may report up to 1.0 credit hours toward the continuing education requirements for license renewal by their state Board of Registered Nurses (BRN). AMA PRA Category 1 Credit™ may be noted on the license renewal application in lieu of a BRN provider number.
Physician Assistants: The National Commission on Certification of Physicians Assistants states that AMA PRA Category 1 Credit™ accredited courses are acceptable for CME requirements for recertification.
- 1.00 AMA PRA Category 1 Credit™City of Hope is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
City of Hope designates this 2021 Pediatric Grand Rounds | Trials and Tribulations: Path Forward in Relapsed/Refractory Neuroblastoma Therapy for a maximum of 1.00 AMA PRA Category 1 Credit™ requirements. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.00 Attendance